Treatment of superficial bladder cancer using BCG as an immunotherapeutic agent has proved effective. Stringent safety procedures have been introduced at Yeovil District Hospital so that this treatment is available to patients with bladder cancer, while ensuring that other patients and staff are protected from the possibility of BCG cross-infection.
Nursing Standard. 14, 37, 45-47. doi: 10.7748/ns2000.05.14.37.45.c2849
or
Alternatively, you can purchase access to this article for the next seven days. Buy now
Are you a student? Our student subscription has content especially for you.
Find out more